Skip to main content

BIODESIX, INC. BDSX INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 57% Share Drop

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Biodesix, Inc. (“Biodesix” or the “Company”) (NASDAQ: BDSX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]

What Happened?

On November 5, 2026, Biodesix announced its third quarter 2026 financial results, reporting third quarter revenue of $24.0 million, below analyst expectations, and reducing its full-year 2026 revenue guidance to $101 million to $103 million from its prior guidance of $108 million to $114 million. Kinross CEO Scott Hutton stated that “execution and timing challenges,” specifically “fewer contributing sales representatives than planned, greater-than-anticipated seasonality in primary care and customer-delayed start of several development services projects,” led to quarterly results that “did not meet our expectations.” Hutton further explained the Company averaged 101 sales representatives during the quarter, below the Company’s second quarter average, due to higher turnover and a hiring pace that did not keep up with attrition and planned growth. Hutton stated, “As a result, a greater portion of our commercial effort was focused on maintaining existing accounts, reducing our capacity to acquire new ordering physicians.” On this news, the price of Biodesix shares declined by $11.31 per share, or approximately 57%, from $19.84 per share on November 5, 2026 to close at $8.53 on November 6, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Biodesix securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.89
+0.00 (0.00%)
AAPL  351.91
+0.00 (0.00%)
AMD  503.41
+0.00 (0.00%)
BAC  49.44
+0.00 (0.00%)
GOOG  277.60
+0.00 (0.00%)
META  618.87
+0.00 (0.00%)
MSFT  506.24
+0.00 (0.00%)
NVDA  155.46
+0.00 (0.00%)
ORCL  115.00
+0.00 (0.00%)
TSLA  380.11
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.